Market Closed -
Other stock markets
|
|
Pre-market 08:51:09 am | ||
0.5862 USD | -1.13% | 0.59 | +0.65% |
Financials (USD)
Sales 2023 * | 485M | Sales 2024 * | 524M | Capitalization | 168M |
---|---|---|---|---|---|
Net income 2023 * | -1.43B | Net income 2024 * | -380M | EV / Sales 2023 * | 2,89x |
Net Debt 2023 * | 1.23B | Net Debt 2024 * | 1.08B | EV / Sales 2024 * | 2,38x |
P/E ratio 2023 * | -0,11x | P/E ratio 2024 * | -0,45x | Employees | 1,700 |
Yield 2023 * | - | Yield 2024 * | - | Free-Float | 98.46% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
1 day | -1.13% | ||
1 week | +14.92% | ||
Current month | +15.35% | ||
1 month | -7.67% | ||
3 months | -34.27% | ||
6 months | -44.70% | ||
Current year | -68.48% |
1 week
0.50
0.64

1 month
0.36
0.73

Current year
0.36
2.94

1 year
0.36
2.94

3 years
0.36
61.59

5 years
0.36
61.59

10 years
0.36
61.59

Managers | Title | Age | Since |
---|---|---|---|
Kenneth Knight
CEO | Chief Executive Officer | 62 | 2020 |
Randal Scott
FOU | Founder | 65 | 2010 |
Thomas R Brida
CMP | Compliance Officer | 52 | 2015 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 66 | 2015 | |
Randal Scott
FOU | Founder | 65 | 2010 |
Eric Aguiar
BRD | Director/Board Member | 61 | 2010 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.83% | 2 M€ | -.--% | - | |
0.69% | 14 M€ | -8.10% |
Date | Price | Change | Volume |
---|---|---|---|
23-12-05 | 0.5862 | -1.13% | 5,686,040 |
23-12-04 | 0.5929 | +2.54% | 8,088,588 |
23-12-01 | 0.5782 | +13.77% | 7,309,324 |
23-11-30 | 0.5082 | -1.78% | 6,067,617 |
23-11-29 | 0.5174 | +1.43% | 6,485,546 |
Delayed Quote Nyse, December 05, 2023 at 04:00 pm EST
More quotes
Invitae Corporation is a medical genetics company. The Company is engaged in delivering genetic testing services, digital health solutions, and health data services that support a lifetime of patient care and improved outcomes. It offers genetic testing across multiple clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases and pharmacogenomics. It applies proprietary design, process automation, robotics and bioinformatics software solutions to expand the use and impact of genetic information in sample processing and complex variant interpretation, allowing medical interpretation at scale. The Company also utilizes digital health solutions to improve ease-of-use and to deliver actionable information about risk, prevention, treatment, and monitoring. The Company has served over 3.6 million patients, and over 2.2 million of those patients have made their information available for data sharing.
Calendar
2024-02-20
- Q4 2023 Earnings Release (Projected)
Trading Rating :
Investor Rating :
ESG Refinitiv :
C+
Sell
Buy

Mean consensus
UNDERPERFORM
Number of Analysts
9
Last Close Price
0.5862USD
Average target price
1.31USD
Spread / Average Target
+123.47%
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-68.48% | 168 M $ | |
+30.82% | 11 714 M $ | |
-2.90% | 3 116 M $ | |
-0.27% | 2 958 M $ | |
+7.00% | 1 854 M $ | |
-1.88% | 1 605 M $ | |
-3.49% | 930 M $ | |
-63.59% | 689 M $ | |
-15.16% | 524 M $ | |
0.00% | 280 M $ |